Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Change in Receivables for 3 consecutive years, with -$79602.0 as the latest value for Q3 2023.

  • Quarterly Change in Receivables fell 1191.93% to -$79602.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$79602.0 through Jun 2024, down 143.45% year-over-year, with the annual reading at -$39881.0 for FY2023, 200.0% down from the prior year.
  • Change in Receivables for Q3 2023 was -$79602.0 at Inhibikase Therapeutics, down from $15083.0 in the prior quarter.
  • The five-year high for Change in Receivables was $332774.0 in Q1 2021, with the low at -$369099.0 in Q3 2021.
  • Average Change in Receivables over 3 years is $10012.8, with a median of $7290.0 recorded in 2022.
  • The sharpest move saw Change in Receivables soared 226.87% in 2022, then tumbled 1191.93% in 2023.
  • Over 3 years, Change in Receivables stood at -$107341.0 in 2021, then skyrocketed by 226.87% to $136180.0 in 2022, then tumbled by 158.45% to -$79602.0 in 2023.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$79602.0, $15083.0, and $24638.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.